
Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.

Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.

Patients with high eosinophil counts appeared to benefit from inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD), while those with low counts did not.

Patients who utilized a patient-reported outcome (PRO) symptom measurement tool reported superior postdischarge outcomes after lung cancer surgery compared with those who received usual care.

President Joe Biden's FDA nominee reaches final confirmation vote; Georgia bill that extends Medicaid coverage for low-income moms advances to House of Representatives; New Mexico bill aims to legalize test strips to detect the presence of fentanyl.

High-risk patients and patients with a history of pulmonary arterial hypertension (PAH) had significantly different cytokine profiles compared with patients with a low risk of the condition.

By making diligent compliance efforts a priority in the years ahead, health plans can shore up existing processes to achieve financial success and ensure risk adjustment as regulatory bodies take aim at organizational missteps.

Several potential biomarkers have emerged, although most still require significant validation before they can be used in the clinic.

The National Clinical Care Commission (NCCC) issued 39 recommendations to improve diabetes prevention and care in the United States.

A new study from North Carolina has investigated individuals’ experiences with and perspectives on their receipt of HIV-related care while incarcerated in 1 of 21 jails in the state.

Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.

Although the COVID-19 pandemic has led to mass slowdowns in drug approvals and biosimilar launches, 2021 signaled a stronger focus on biosimilars going forward, with new regulatory bills and a crackdown on anticompetitive practices.

Geoffrey Boyce, CEO of Array Behavioral Care, explains how behavioral health care differs between in-person and telehealth care.

The FDA delays its decision on Pfizer/BioNTech’s COVID-19 vaccine in young children; the Federal Trade Commission (FTC) will vote on whether to investigate pharmacy benefit managers (PBMs); nearly half of high-volume antibiotic prescribers are located in Southern states.

Research suggests a shorter 5-day antibiotic regimen for childhood community-acquired pneumonia, instead of 10 days, can optimize treatment efficacy while reducing unnecessary antibiotic use.

The organization announced a partnership with over 1000 nephrology providers to help implement CMS’ new Kidney Care Choices models beginning this year.

The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.

A statement from NCCN’s Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis said that the panel “endorses vaccination for all eligible persons based on FDA-approved indications or emergency use authorization” and emphasized the need for everyone to be fully vaccinated—including third doses.

Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses challenges for Tennessee Oncology and community oncology in general.

Patients with non–small cell lung cancer (NSCLC) reported superior mental health well-being during the COVID-19 pandemic compared with a control population that did not have cancer.

Contrary to research done on adults, a recent study found that children may be highly sensitive to light exposure of any intensity before bedtime.

Eosinophilic esophagitis is a complex disorder with significant health burdens and a recent review described how management strategies have changed over time.

Affecting up to 1 in 10 people worldwide, rosacea has a complex pathophysiology that remains inadequately understood, and research has hinted at multiple inflammatory and immune mediated processes underlying the condition.

Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.

While the number of trials for cancer immunotherapies grew significantly, combination therapies being studied increased while monotherapies decreased.

Through the use of patient testimonials as well as analysis of data from a study of patients with spinal muscular atrophy (SMA), researchers were able to describe patient-centered “meaningful outcomes” in the 32-item Motor Function Measure.

A study published on World Cholangiocarcinoma Day outlines characteristics of disease subtypes and the strong links to lifestyle factors, such as obesity and alcohol use.

This new study from investigators at University of Calgary investigated the potential of midwall striae fibrosis to predict hospital admission for heart failure.

More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.

While it is known that the promotion of physical activity can improve asthma symptoms and quality of life—and is even recommended in asthma guidelines— such behavior change is often difficult due to lack of funding or reimbursement for pulmonary rehabilitation or for other reasons.

This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
